James S ODonnell
Overview
Explore the profile of James S ODonnell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
3165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rehill A, McCluskey S, Ledwith A, Ryan T, Unlu B, Leon G, et al.
Sci Adv
. 2025 Mar;
11(10):eads0105.
PMID: 40053582
The pathogenic basis for increased thrombotic risk in individuals with inflammatory diseases is poorly understood. Myeloid cell "trained immunity" describes persistent innate immune cell memory arising from prior exposure to...
2.
Leon G, Klavina P, Rehill A, Cooper S, Dominik A, Basavarajappa S, et al.
Nat Commun
. 2025 Feb;
16(1):1677.
PMID: 39956825
Patients with inflammatory bowel disease (IBD) have an increased risk of venous thromboembolism (VTE), but the underlying mechanistic basis remains poorly defined. Here, we find that colitogenic CD4 T cells...
3.
Monard A, Mussert C, van Duijl T, Kruip M, Henskens Y, van den Biggelaar M, et al.
Res Pract Thromb Haemost
. 2024 Dec;
8(8):102625.
PMID: 39687924
In more than half of the individuals with a clinically relevant bleeding tendency who are referred to hemostasis experts, no biological etiology can be found after extensive laboratory testing. These...
4.
Blatny J, Astermark J, Catarino C, Dolan G, Fijnvandraat K, Hermans C, et al.
Ther Adv Hematol
. 2024 Oct;
15:20406207241285143.
PMID: 39381602
Over recent decades, management of people with hemophilia (PwH) has been greatly improved by scientific advances that have resulted in a rich and varied therapeutic landscape. Nevertheless, treatment limitations continue...
5.
ODonnell J, Baker R, Atiq F
J Thromb Haemost
. 2024 Sep;
22(12):3383-3388.
PMID: 39265913
The 2021 ASH ISTH NHF WFH guidelines recommendation that patients with von Willebrand factor (VWF) levels of 30 to 50 IU/dL and an increased bleeding phenotype be categorized as type...
6.
Colleran R, Fitzgerald S, Rai H, McGovern L, Byrne R, Mansur A, et al.
Sci Rep
. 2024 Sep;
14(1):21229.
PMID: 39261512
SETANTA (Study of HEarT DiseAse and ImmuNiTy After COVID-19 in Ireland) study aimed to investigate symptom burden and incidence of cardiac abnormalities after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19...
7.
Seidizadeh O, Eikenboom J, Denis C, Flood V, James P, Lenting P, et al.
Nat Rev Dis Primers
. 2024 Jul;
10(1):51.
PMID: 39054329
von Willebrand disease (VWD) is the most common inherited bleeding disorder. The disorder is characterized by excessive mucocutaneous bleeding. The most common bleeding manifestations of this condition include nosebleeds, bruising,...
8.
Atiq F, Rawley O, OSullivan J, Ozbil M, Doherty D, Cooke N, et al.
J Thromb Haemost
. 2024 Jul;
22(10):2752-2760.
PMID: 38996914
Background: von Willebrand factor (VWF)-R1205H variant (Vicenza) results in markedly enhanced VWF clearance in humans that has been shown to be largely macrophage-mediated. However, the biological mechanisms underlying this enhanced...
9.
Chion A, Byrne C, Atiq F, Doherty D, Aguila S, Fazavana J, et al.
Blood
. 2024 Jul;
144(13):1445-1456.
PMID: 38996211
Rondaptivon pegol (previously BT200) is a pegylated RNA aptamer that binds to the A1 domain of von Willebrand factor (VWF). Recent clinical trials demonstrated that BT200 significantly increased plasma VWF-factor...
10.
Kelly C, Thomas W, Baker R, ODonnell J, Sanchez-Luceros A, Lavin M
J Thromb Haemost
. 2024 Jun;
22(10):2900-2909.
PMID: 38866246
Background: Bleeding disorder of unknown cause (BDUC) is characterized by a bleeding phenotype in the setting of normal hemostatic testing. No standardized diagnostic criteria or treatment algorithms exist for people...